FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241941246> ?p ?o ?g. }

• W4241941246 endingPage "155" @default.
• W4241941246 startingPage "LB" @default.
• W4241941246 abstract "Abstract Objective: Therapy with Tumor Treating Fields (TTFields) in combination with adjuvant temozolomide following surgical resection and radiochemotherapy significantly increased survival rates in patients with newly diagnosed glioblastoma (ndGBM) in the phase III trial EF-14. The importance of a high compliance/usage rate was supported by a recently published subgroup analysis, revealing a strong correlation of adherence to TTFields therapy with prolonged overall survival (OS). A compliance rate of 75% and more was demonstrated to be a beneficial independent prognostic factor for OS. Here, TTFields therapy adherence of 36 high-grade glioma (HGG) patients is reported. Methods: 36 patients diagnosed with HGG received TTFields therapy, amongst them 28 patients diagnosed with GBM and 8 patients with astrocytoma WHO°III. Patients were introduced to the therapy during neurooncologic consultation hours. For assessment of adherence to TTFields therapy, the compliance/usage reports generated at the monthly technical check of the device were analyzed. Results: At initiation of therapy, the median age of HGG patients was 53.5 years (range 29-67 years). 21 of the 28 GBM patients were diagnosed with ndGBM and the remaining ones had recurrences (rGBM). In these patients, the gender distribution female to male was 1:1.15, which represents a higher ratio of female patients compared to the typical GBM population with 1:1.64. At the time point of data cut-off, ndGBM patients were on TTFields therapy for a median of 6.9 months with a median compliance/usage rate of 84.2%. Regarding therapy adherence, no significant differences were observed between female (84.3%) and male (81.1%) patients. Moreover, comparison between patients with ndGBM and recurrent GBM (rGBM) showed no significant difference in therapy adherence with a median compliance of 71.1% in rGBM patients. For patients diagnosed with astrocytoma WHO°III a compliance rate of 84.5% was reported. Conclusion: In the reported patients receiving TTFields therapy a high median compliance to TTFields therapy was observed, irrespective of sex and diagnosis. No significant differences regarding the compliance/usage rate was detected between the different groups. TTFields therapy was well accepted by all HGG patients, in particular by female GBM patients. Across all groups, the median compliance/usage rate was substantially above the independent prognostic threshold of 75%. In conclusion, TTFields therapy can be recommended to all eligible patients with HGG. Citation Format: Carsten Hagemann, Judith Weiland, Nadine Lilla, Thomas Linsenmann, Ralf-Ingo Ernestus, Mario Löhr, Almuth F. Kessler. Adherence to tumor treating fields (TTFields) in high-grade glioma patients - a single center experience [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-155." @default.
• W4241941246 created "2022-05-12" @default.
• W4241941246 creator A5010337152 @default.
• W4241941246 creator A5018022781 @default.
• W4241941246 creator A5056537404 @default.
• W4241941246 creator A5056787795 @default.
• W4241941246 creator A5057149436 @default.
• W4241941246 creator A5060780761 @default.
• W4241941246 creator A5076791119 @default.
• W4241941246 date "2019-07-01" @default.
• W4241941246 modified "2023-09-27" @default.
• W4241941246 title "Abstract LB-155: Adherence to tumor treating fields (TTFields) in high-grade glioma patients - a single center experience" @default.
• W4241941246 doi "https://doi.org/10.1158/1538-7445.am2019-lb-155" @default.
• W4241941246 hasPublicationYear "2019" @default.
• W4241941246 type Work @default.
• W4241941246 citedByCount "0" @default.
• W4241941246 crossrefType "journal-article" @default.
• W4241941246 hasAuthorship W4241941246A5010337152 @default.
• W4241941246 hasAuthorship W4241941246A5018022781 @default.
• W4241941246 hasAuthorship W4241941246A5056537404 @default.
• W4241941246 hasAuthorship W4241941246A5056787795 @default.
• W4241941246 hasAuthorship W4241941246A5057149436 @default.
• W4241941246 hasAuthorship W4241941246A5060780761 @default.
• W4241941246 hasAuthorship W4241941246A5076791119 @default.
• W4241941246 hasConcept C121608353 @default.
• W4241941246 hasConcept C126322002 @default.
• W4241941246 hasConcept C141071460 @default.
• W4241941246 hasConcept C143998085 @default.
• W4241941246 hasConcept C2776694085 @default.
• W4241941246 hasConcept C2777389519 @default.
• W4241941246 hasConcept C2777982462 @default.
• W4241941246 hasConcept C2778227246 @default.
• W4241941246 hasConcept C2908647359 @default.
• W4241941246 hasConcept C502942594 @default.
• W4241941246 hasConcept C71924100 @default.
• W4241941246 hasConcept C99454951 @default.
• W4241941246 hasConceptScore W4241941246C121608353 @default.
• W4241941246 hasConceptScore W4241941246C126322002 @default.
• W4241941246 hasConceptScore W4241941246C141071460 @default.
• W4241941246 hasConceptScore W4241941246C143998085 @default.
• W4241941246 hasConceptScore W4241941246C2776694085 @default.
• W4241941246 hasConceptScore W4241941246C2777389519 @default.
• W4241941246 hasConceptScore W4241941246C2777982462 @default.
• W4241941246 hasConceptScore W4241941246C2778227246 @default.
• W4241941246 hasConceptScore W4241941246C2908647359 @default.
• W4241941246 hasConceptScore W4241941246C502942594 @default.
• W4241941246 hasConceptScore W4241941246C71924100 @default.
• W4241941246 hasConceptScore W4241941246C99454951 @default.
• W4241941246 hasIssue "13_Supplement" @default.
• W4241941246 hasLocation W42419412461 @default.
• W4241941246 hasOpenAccess W4241941246 @default.
• W4241941246 hasPrimaryLocation W42419412461 @default.
• W4241941246 hasRelatedWork W1971687732 @default.
• W4241941246 hasRelatedWork W2073885660 @default.
• W4241941246 hasRelatedWork W2152636851 @default.
• W4241941246 hasRelatedWork W2163669784 @default.
• W4241941246 hasRelatedWork W2362511750 @default.
• W4241941246 hasRelatedWork W2478183617 @default.
• W4241941246 hasRelatedWork W2891704147 @default.
• W4241941246 hasRelatedWork W3036597250 @default.
• W4241941246 hasRelatedWork W3094560227 @default.
• W4241941246 hasRelatedWork W3199235828 @default.
• W4241941246 hasVolume "79" @default.
• W4241941246 isParatext "false" @default.
• W4241941246 isRetracted "false" @default.
• W4241941246 workType "article" @default.